Medical treatment of Parkinson disease.
The cardinal characteristics of Parkinson disease (PD) include resting tremor, rigidity, and bradykinesia. Patients may also develop autonomic dysfunction, cognitive changes, psychiatric symptoms, sensory complaints, and sleep disturbances. The treatment of motor and non-motor symptoms of Parkinson disease is addressed in this article.
Stacy
Mark
M
Division of Neurology, Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA. stacy002@mc.duke.edu
D000547:Amantadine / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D065098:Catechol O-Methyltransferase Inhibitors; D003072:Cognition Disorders / Q000188:drug therapy; D003342:Corpus Striatum / Q000187:drug effects / Q000503:physiopathology; D004068:Digestive System Physiological Phenomena / Q000187:drug effects; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007024:Hypotension, Orthostatic / Q000188:drug therapy; D007980:Levodopa / Q000627:therapeutic use; D001523:Mental Disorders / Q000188:drug therapy; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D009043:Motor Activity / Q000187:drug effects; D009069:Movement Disorders / Q000188:drug therapy* / Q000503:physiopathology; D009474:Neurons / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D012893:Sleep Wake Disorders / Q000188:drug therapy; D013378:Substantia Nigra / Q000187:drug effects / Q000503:physiopathology
D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D018491:Dopamine Agonists; D004791:Enzyme Inhibitors; D008996:Monoamine Oxidase Inhibitors; D007980:Levodopa; D000547:Amantadine